Developer docs
API playgroundTry for free, no card

Search company profiles

enGene

Full company profile

uuid00003zl

Namestring
enGene
Legal namestring
enGene Inc.
Websiteurl
engene.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid (formerly EG-70), a non-viral gene therapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company was founded in Canada in 2012 and became publicly traded on NASDAQ in November 2023 through a business combination with Forbion European Acquisition Corp.; it was renamed enGene Therapeutics Inc. in April 2026 to reflect its planned transition toward becoming a commercial organization. Its lead candidate is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform, a non-viral gene delivery technology that enables localized, intravesical administration of therapeutic genetic material designed to drive expression of immune-activating payloads (including IL-12 and double-stranded RNAs) directly at the bladder tumor site.

The company's clinical lead, detalimogene, is being studied in the LEGEND Phase 2 trial across multiple cohorts of NMIBC patients, including BCG-unresponsive, BCG-naïve, and BCG-exposed populations with or without carcinoma in situ, as well as BCG-unresponsive papillary-only disease. Pivotal Cohort 1 data showed a 54% complete response rate at any time (67/124 patients) and a 3.2% rate of progression to muscle-invasive or higher disease, with the FDA having granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations and selected detalimogene for the CMC Development and Readiness Pilot Program. The company positions detalimogene as an "off-the-shelf" intravesical therapy intended to fit into existing urology clinic workflows without specialized handling, cold-chain storage, urine bleaching, or extensive staff training.

enGene is currently pre-revenue with no commercial products. Its planned business model contemplates one-time-per-treatment pricing for detalimogene administered through urology practices and hospitals, supported by an enterprise field sales motion aimed at the approximately 17,000 addressable BCG-unresponsive NMIBC patients annually in the US. The company has funded operations through multiple capital transactions since its 2023 listing, including a $200M oversubscribed private placement in February 2024, a ~$130M public offering in November 2025, and a $125M expanded debt facility with Hercules Capital announced in January 2026. In June 2026, the company announced a 50% workforce reduction as a cash-conservation measure ahead of a critical regulatory readout and Biologics License Application submission targeted for the second half of 2026.

Short descriptiontext

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer, using its proprietary DDX platform. Pre-revenue, the company is targeting FDA approval and a 2027 commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, bladder cancer treatment, non-viral delivery, biologic drug development, mucosal therapeutics
Industry2 codes
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Detalimogene Commercialization
TypeOne Time License
Description

enGene is a clinical-stage company developing detalimogene voraplasmid for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company plans to commercialize its gene therapy product following potential FDA approval, targeting urology practices and hospitals. Currently pre-revenue with no commercial products approved.

engene.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

enGene is a clinical-stage biopharmaceutical company developing detalimogene voraplasmid, an investigational non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy is delivered intravesically using the company's proprietary DDX (Dually Derivatized Oligochitosan) platform, which enables localized delivery of genetic medicines to mucosal tissues such as the bladder. The company is preparing for potential FDA approval and commercial launch in 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 54% complete response rate at any time in BCG-unresponsive NMIBC patients with CIS (67/124)
+4 more records
Product overview1 text field

enGene is a clinical-stage biotechnology company with a single-product focus developing detalimogene voraplasmid (EG-70), a non-viral gene therapy for non-muscle invasive bladder cancer. The therapy is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform technology, which enables localized delivery of genetic medicines to mucosal tissues. Detalimogene is currently in Phase 2 clinical trials (LEGEND study) across multiple patient cohorts and has received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is preparing for potential FDA approval and commercial launch in 2027.

Product and service1 record
1Detalimogene Voraplasmid (EG-70)
CategoryGene Therapy / Biopharmaceutical
Description

Investigational non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC) that delivers genetic instructions to bladder cells, enabling them to produce therapeutic proteins that activate local innate and adaptive immune responses against cancer. Designed for BCG-unresponsive patients with carcinoma in situ (CIS) and papillary-only NMIBC to delay or avoid radical cystectomy. Administered intravesically as an off-the-shelf therapy with no cold-chain storage requirement and one-hour dwell time.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

enGene supports BCAN as part of its community investment initiatives, participating in patient advocacy activities including Walk to End Bladder Cancer to foster connection between employees and the company's mission.

2Life Science Cares Boston
Strategic tierMinorTypeStrategic or Co-development Partner
Description

enGene supports Life Science Cares Boston as a high-impact nonprofit organization, aligning with its commitment to community investment and corporate responsibility.

engene.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

enGene participates in volunteer and fundraising opportunities including the Special Olympics Massachusetts BioBall event as part of its employee engagement and community support initiatives.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CG Oncology is developing CG0070, an oncolytic adenovirus-based intravesical therapy for BCG-unresponsive NMIBC. It is the closest late-stage head-to-head competitor to detalimogene, targeting the same indication with a different but also intravesical mechanism.

TypeBroad incumbent
Description

Astellas co-markets Ferring's Adstiladrin in the U.S. for BCG-unresponsive NMIBC. As a large global urology/oncology incumbent with gene-therapy commercialization experience, it is a broader peer and potential BD partner for enGene.

TypeBroad incumbent
Description

Johnson & Johnson's Balversa (erdafitinib) is approved for FGFR-altered urothelial carcinoma, giving it a presence in advanced bladder cancer. J&J is a broad incumbent in urologic oncology with the resources to compete with or acquire late-stage NMIBC assets.

TypeDirect peer
Description

UroGen Pharma is developing UGN-102 (mitomycin) for NMIBC and has an established urology commercial footprint with Jelmyto. It is a direct intravesical-NMIBC competitor with a broader urology commercial platform.

TypeBroad incumbent
Description

uniQure is an established gene therapy company with AAV-based products approved or in late-stage trials for CNS, cardiovascular, and metabolic diseases. It is a broader incumbent peer operating in the gene therapy modality space.

TypeDirect peer
Description

Merck's Keytruda (pembrolizumab) received FDA approval in 2020 for BCG-unresponsive NMIBC. It is an established approved competing therapy in the same BCG-unresponsive NMIBC segment that detalimogene targets.

7Kintor Pharmaceutical
TypeEmerging player
Description

Kintor is developing therapies for urologic cancers including NMIBC and prostate cancer. It is an emerging peer in the same urologic oncology space with partial clinical-stage overlap.

TypeEmerging player
Description

MeiraGTx is a clinical-stage gene therapy company with proprietary viral and non-viral delivery platforms for ocular, CNS, and metabolic diseases. It is an emerging peer on gene-therapy platform technology rather than indication overlap.

TypeDirect peer
Description

ImmunityBio's Anktiva (N-803, nogapendekin alfa inbakicept-pmln) was FDA-approved in 2024 for BCG-unresponsive NMIBC with CIS. It is a directly competing approved therapy in enGene's lead indication.

TypeDirect peer
Description

Ferring, partnered with Astellas, markets Adstiladrin (nadofaragene firadenovec), an intravesical gene therapy approved in late 2024 for BCG-unresponsive NMIBC. This is an approved gene-therapy competitor to detalimogene in the same setting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

enGene

Biopharmaceuticalsengene.com

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer, using its proprietary DDX platform. Pre-revenue, the company is targeting FDA approval and a 2027 commercial launch.

What enGene does

enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid (formerly EG-70), a non-viral gene therapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company was founded in Canada in 2012 and became publicly traded on NASDAQ in November 2023 through a business combination with Forbion European Acquisition Corp.; it was renamed enGene Therapeutics Inc. in April 2026 to reflect its planned transition toward becoming a commercial organization. Its lead candidate is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform, a non-viral gene delivery technology that enables localized, intravesical administration of therapeutic genetic material designed to drive expression of immune-activating payloads (including IL-12 and double-stranded RNAs) directly at the bladder tumor site.

The company's clinical lead, detalimogene, is being studied in the LEGEND Phase 2 trial across multiple cohorts of NMIBC patients, including BCG-unresponsive, BCG-naïve, and BCG-exposed populations with or without carcinoma in situ, as well as BCG-unresponsive papillary-only disease. Pivotal Cohort 1 data showed a 54% complete response rate at any time (67/124 patients) and a 3.2% rate of progression to muscle-invasive or higher disease, with the FDA having granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations and selected detalimogene for the CMC Development and Readiness Pilot Program. The company positions detalimogene as an "off-the-shelf" intravesical therapy intended to fit into existing urology clinic workflows without specialized handling, cold-chain storage, urine bleaching, or extensive staff training.

enGene is currently pre-revenue with no commercial products. Its planned business model contemplates one-time-per-treatment pricing for detalimogene administered through urology practices and hospitals, supported by an enterprise field sales motion aimed at the approximately 17,000 addressable BCG-unresponsive NMIBC patients annually in the US. The company has funded operations through multiple capital transactions since its 2023 listing, including a $200M oversubscribed private placement in February 2024, a ~$130M public offering in November 2025, and a $125M expanded debt facility with Hercules Capital announced in January 2026. In June 2026, the company announced a 50% workforce reduction as a cash-conservation measure ahead of a critical regulatory readout and Biologics License Application submission targeted for the second half of 2026.

enGene firmographics

Firmographics
Name
enGene
Legal name
enGene Inc.
Website
https://engene.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
enGene is a clinical-stage biotechnology company developing detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer, using its proprietary DDX platform. Pre-revenue, the company is targeting FDA approval and a 2027 commercial launch.
Ownership category
akta.pro rank

enGene industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Gene therapy
  • Bladder cancer treatment
  • Non-viral delivery
  • Biologic drug development
  • Mucosal therapeutics

Where enGene is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

enGene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Detalimogene Commercialization: enGene is a clinical-stage company developing detalimogene voraplasmid for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company plans to commercialize its gene therapy product following potential FDA approval, targeting urology practices and hospitals. Currently pre-revenue with no commercial products approved.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

enGene product offering

Product offering

Core offering

enGene is a clinical-stage biopharmaceutical company developing detalimogene voraplasmid, an investigational non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy is delivered intravesically using the company's proprietary DDX (Dually Derivatized Oligochitosan) platform, which enables localized delivery of genetic medicines to mucosal tissues such as the bladder. The company is preparing for potential FDA approval and commercial launch in 2027.

Product overview

enGene is a clinical-stage biotechnology company with a single-product focus developing detalimogene voraplasmid (EG-70), a non-viral gene therapy for non-muscle invasive bladder cancer. The therapy is powered by the proprietary DDX (Dually Derivatized Oligochitosan) platform technology, which enables localized delivery of genetic medicines to mucosal tissues. Detalimogene is currently in Phase 2 clinical trials (LEGEND study) across multiple patient cohorts and has received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is preparing for potential FDA approval and commercial launch in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • Detalimogene Voraplasmid (EG-70) Investigational non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC) that delivers genetic instructions to bladder cells, enabling them to produce therapeutic proteins that activate local innate and adaptive immune responses against cancer. Designed for BCG-unresponsive patients with carcinoma in situ (CIS) and papillary-only NMIBC to delay or avoid radical cystectomy. Administered intravesically as an off-the-shelf therapy with no cold-chain storage requirement and one-hour dwell time.

Quantifiable outcome

  • 54% complete response rate at any time in BCG-unresponsive NMIBC patients with CIS (67/124)
  • +4 more outcomes

Companies that use enGene

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

enGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

enGene partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Bladder Cancer Advocacy Network (BCAN)minorStrategic or Co-development PartnerenGene supports BCAN as part of its community investment initiatives, participating in patient advocacy activities including Walk to End Bladder Cancer to foster connection between employees and the company's mission.
  • Life Science Cares BostonminorStrategic or Co-development PartnerenGene supports Life Science Cares Boston as a high-impact nonprofit organization, aligning with its commitment to community investment and corporate responsibility.
  • Special Olympics MassachusettsminorStrategic or Co-development PartnerenGene participates in volunteer and fundraising opportunities including the Special Olympics Massachusetts BioBall event as part of its employee engagement and community support initiatives.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

enGene competitors and assessment

Company assessment

Direct peers

  • CG Oncology: CG Oncology is developing CG0070, an oncolytic adenovirus-based intravesical therapy for BCG-unresponsive NMIBC. It is the closest late-stage head-to-head competitor to detalimogene, targeting the same indication with a different but also intravesical mechanism.
  • UroGen Pharma: UroGen Pharma is developing UGN-102 (mitomycin) for NMIBC and has an established urology commercial footprint with Jelmyto. It is a direct intravesical-NMIBC competitor with a broader urology commercial platform.
  • Merck & Co. Merck's Keytruda (pembrolizumab) received FDA approval in 2020 for BCG-unresponsive NMIBC. It is an established approved competing therapy in the same BCG-unresponsive NMIBC segment that detalimogene targets.
  • ImmunityBio: ImmunityBio's Anktiva (N-803, nogapendekin alfa inbakicept-pmln) was FDA-approved in 2024 for BCG-unresponsive NMIBC with CIS. It is a directly competing approved therapy in enGene's lead indication.
  • Ferring Pharmaceuticals: Ferring, partnered with Astellas, markets Adstiladrin (nadofaragene firadenovec), an intravesical gene therapy approved in late 2024 for BCG-unresponsive NMIBC. This is an approved gene-therapy competitor to detalimogene in the same setting.

Broad incumbents

  • Astellas Pharma: Astellas co-markets Ferring's Adstiladrin in the U.S. for BCG-unresponsive NMIBC. As a large global urology/oncology incumbent with gene-therapy commercialization experience, it is a broader peer and potential BD partner for enGene.
  • Johnson & Johnson: Johnson & Johnson's Balversa (erdafitinib) is approved for FGFR-altered urothelial carcinoma, giving it a presence in advanced bladder cancer. J&J is a broad incumbent in urologic oncology with the resources to compete with or acquire late-stage NMIBC assets.
  • uniQure: uniQure is an established gene therapy company with AAV-based products approved or in late-stage trials for CNS, cardiovascular, and metabolic diseases. It is a broader incumbent peer operating in the gene therapy modality space.

Emerging players

  • Kintor Pharmaceutical: Kintor is developing therapies for urologic cancers including NMIBC and prostate cancer. It is an emerging peer in the same urologic oncology space with partial clinical-stage overlap.
  • MeiraGTx: MeiraGTx is a clinical-stage gene therapy company with proprietary viral and non-viral delivery platforms for ocular, CNS, and metabolic diseases. It is an emerging peer on gene-therapy platform technology rather than indication overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

enGene social profiles

Digital presence

enGene compliance and trust

Trust signal

Compliance2 records

enGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

enGene leadership team

Management profile

Number of profiles

Profiles8 records

enGene subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

enGene funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

enGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about enGene

What does enGene do?

enGene is a clinical-stage biopharmaceutical company developing detalimogene voraplasmid, an investigational non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy is delivered intravesically using the company's proprietary DDX (Dually Derivatized Oligochitosan) platform, which enables localized delivery of genetic medicines to mucosal tissues such as the bladder. The company is preparing for potential FDA approval and commercial launch in 2027.

Is enGene a public or private company?

enGene is a public company. It is classified as public and is currently operating.

When was enGene founded?

enGene was founded in 2012. It employs 101 to 250 people.

Where is enGene based?

enGene is headquartered in Boston, United States, in the North America region.

How does enGene make money?

One revenue line is on record: detalimogene Commercialization.

Who are enGene's main competitors?

Direct peers on record are CG Oncology, UroGen Pharma, Merck & Co., ImmunityBio and Ferring Pharmaceuticals. Broad incumbents are Astellas Pharma, Johnson & Johnson and uniQure. Emerging players are Kintor Pharmaceutical and MeiraGTx.

Does enGene have an API?

No public API is recorded for enGene.

What industry is enGene in?

enGene's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAM, Nephrology & Urology Pharmaceuticals, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaenGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 TranscriptenGene Therapeutics CEO Ronald Cooper presented at the UBS Global Biopharma Conference, discussing its nonviral gene therapy platform and product detalimogene for non-muscle invasive bladder cancer. The company plans to file the BLA by the end of 2026 and expects approval next year.Investing.comenGene at UBS Global Biopharma Conference 2026: bladder cancer push advancesenGene presented updated LEGEND study data for its bladder cancer therapy detalimogene voraplasmid at the UBS Global Biopharma Conference 2026, showing improved response durability and a clean safety profile. The company plans to file a biologics license application by end of 2024, expecting FDA approval by 2027. It also outlined a surfactant cohort to improve bladder penetration, with mid-2025 data expected.Seeking AlphaenGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBCenGene Therapeutics downgraded its detalimogene stock from Buy to Sell after updated Cohort 1 data showed any-time CR of 56% and median duration of response of 43%. The company plans to file a BLA by end of 2026, but efficacy remains uncompetitive against Johnson & Johnson's INLEXZO and CG Oncology's cretostimogene.TradingViewLeerink Partners upgrades enGene Therapeutics to Outperform from Market Perform, sets price target at $5Leerink Partners upgraded enGene Therapeutics to Outperform from Market Perform and set a price target of $5. The target implies an upside of 119.3% from the Nov 12 close of $2.28.Investing.comWhy is enGene Therapeutics stock rallying today?enGene Therapeutics stock rose 5% in pre-open trading after the company released improved efficacy data from its Phase 2 LEGEND trial and confirmed FDA alignment on a planned Biologics License Application. The updated data showed a complete response rate of 56% and a 12-month complete response rate of 24%, with the company expecting to submit the BLA by year-end 2026.TradingViewPiper Sandler upgrades enGene Therapeutics to Overweight from Neutral, keeps price target at $4Piper Sandler upgraded enGene Therapeutics to Overweight from Neutral, keeping its price target at $4. The target implies a 122.2% upside from the Nov 11 close of $1.80.Seeking AlphaenGene reports positive LEGEND trial data, plans detalimogene BLA submissionenGene Therapeutics reported positive updated results from Cohort 1 of its Phase 2 LEGEND trial for detalimogene in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The company expects data from 125 patients to form the basis for a detalimogene BLA submission.The future of tradingenGene Presents 56% Complete Response Rate for Detalimogene in Bladder Cancer StudyenGene Therapeutics reported a 56% complete response rate for detalimogene in 120 evaluable patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. The company plans to initiate its biologics license application in the fourth quarter of 2026, targeting approval in 2027, with six-month data expected in mid-2027.The future of tradingenGene Publishes Presentation on LEGEND Trial Interim ResultsenGene Therapeutics published interim data from its LEGEND trial for detalimogene in high-risk non-muscle-invasive bladder cancer. The drug achieved a 56% complete response rate among 120 patients, with a median response duration of 10.1 months. A biologics license application is planned for Q4 2026, with potential approval in 2027.MarketBeatenGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update PathenGene highlighted preclinical findings showing that combining its investigational gene therapy detalimogene with a polidocanol surfactant rinse significantly increased localized immune response in animal models. The company expects to report six-month complete response data from the ongoing surfactant cohort in mid-2027 while planning to submit a biologics license application for the non-surfactant version based on current pivotal cohort results. Community urologists also discussed the treatment burden of high-risk non-muscle invasive bladder cancer, emphasizing the need for bladder-sparing options that balance efficacy with patient tolerability and convenience.